ARTICLE | Clinical News
AIR001: Ph I/II started
March 17, 2017 1:05 PM UTC
Mast Therapeutics said the University of Pittsburgh, (Pittsburgh, Pa.) began an open-label, dose-escalation, U.S. Phase I/II trial to evaluate AIR001. Mast will provide the compound and nebulizers for...
BCIQ Company Profiles